UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

SCHEDULE TO

(Amendment No. 1)

(Rule 14d-100)

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

PFIZER INC.

(Name of Subject Company (Issuer) and Filing Person (Offeror))

 

 

Common Stock, $0.05 Par Value

(Title of Class of Securities)

717081103

(CUSIP Number of Class of Securities)

 

 

Amy W. Schulman

Executive Vice President

and General Counsel

Pfizer Inc.

235 East 42nd Street

New York, New York 10017-5755

(212) 733-2323

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

Copies to:

Stacy J. Kanter, Esq.

Thomas W. Greenberg, Esq.

Skadden Arps, Slate, Meagher & Flom LLP

Four Times Square

New York, New York 10036

(212) 735-3000

 

 

CALCULATION OF FILING FEE

 

Transaction Valuation(1)		Amount of Filing Fee(2)
$12,886,481,522		$1,757,716

(1)

This valuation assumes the acquisition of up to 433,450,438 shares of common stock, par value $0.05 per share, of Pfizer Inc. in exchange for shares of Class A common stock, par value $0.01 per share, of Zoetis Inc. held by Pfizer Inc. Estimated solely for purposes of calculating the filing fee pursuant to Rule 0-11(a)(4) under the Securities Exchange Act of 1934, based on the product of (i) $29.73, the average of the high and low sale prices of Pfizer Inc. common stock on the New York Stock Exchange on May 21, 2013 and (ii) 433,450,438, the maximum number of shares of Pfizer Inc. common stock to be acquired in the exchange offer (based on the indicative exchange ratio of 0.9251 in effect following the close of trading on the New York Stock Exchange on May 21, 2013, the last trading day prior to commencement of the exchange offer).

(2)	Computed in accordance with Rule 0-11(a)(4) and Rule 0-11(b) under the Securities Exchange Act of 1934.

 

x	Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

Amount Previously Paid: $1,825,151		Filing Party: Zoetis Inc.
Form or Registration No.: Registration Statement on Form S-4 (No. 333-188750).		Date Filed: May 22, 2013

 

¨	Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transaction to which the statement relates:

 

¨

third-party tender offer subject to Rule 14d-1

 

x

issuer tender offer subject to Rule 13e-4

 

¨

going-private transaction subject to Rule 13e-3

 

¨

amendment to Schedule 13D under Rule 13d-2

Check the following box if the filing is a final amendment reporting the results of the tender offer:    ¨  If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

 

¨	Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

 

¨	Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

 

 

 

---

This Tender Offer Statement on Schedule TO (this “Schedule TO”) is filed by Pfizer Inc. (“Pfizer”), a Delaware corporation. This Schedule TO relates to the offer by Pfizer to exchange up to 400,985,000 shares of Class A common stock, par value $0.01 per share (“Zoetis common stock”), of Zoetis Inc. (“Zoetis”), a Delaware corporation, for shares of common stock, par value $0.05 per share (“Pfizer common stock”), of Pfizer, upon the terms and subject to the conditions set forth in the Prospectus, dated June 3, 2013 (the “Prospectus”) and the related Letter of Transmittal and instructions thereto (the “Letter of Transmittal”) (which, together with any amendments or supplements thereto, collectively constitute the “Exchange Offer”). In connection with the Exchange Offer, Zoetis has filed under the Securities Act of 1933, as amended (the “Securities Act”), a registration statement on Form S-4 (Registration No. 333-188750) (the “Registration Statement”) to register the shares of Zoetis common stock offered in exchange for shares of Pfizer common stock tendered in the Exchange Offer. The information set forth in the Prospectus and the Letter of Transmittal is incorporated herein by reference in response to all the items of this Schedule TO, except as otherwise set forth below.

 

Item 1.

Summary Term Sheet.

Summary Term Sheet. The information set forth in the sections of the Prospectus entitled “Questions and Answers About the Exchange Offer” and “Summary” are incorporated herein by reference.

 

Item 2.

Subject Company Information.

(a) Name and Address. The name of the issuer is Pfizer Inc. The principal executive offices of Pfizer are located at 235 East 42nd Street, New York, New York 10017. Its telephone number at such office is (212) 733-2323. Reference is made to the information set forth under the heading “Summary—The Companies” in the Prospectus, which is incorporated herein by reference.

(b) Securities. Shares of Pfizer common stock are the subject securities in the Exchange Offer. Reference is made to the information relating to Pfizer common stock set forth under the heading “The Exchange Offer—Terms of the Exchange Offer” in the Prospectus, which is incorporated herein by reference.

(c) Trading Market and Price. Reference is made to the information relating to Pfizer common stock set forth under the heading “Summary—Market Price and Dividend Information” in the Prospectus, which is incorporated herein by reference.

 

Item 3.

Identity and Background of Filing Person.

(a) Name and Address. The filing person is the subject company. Reference is made to the information set forth under the headings “Summary—The Companies” and “Security Ownership of Certain Beneficial Owners and Management of Pfizer and Zoetis” in the Prospectus, which is incorporated herein by reference.

 

Item 4.

Terms of the Transaction.

(a) Material Terms. Reference is made to the information set forth under the headings “Questions and Answers about the Exchange Offer”, “The Transaction”, “The Exchange Offer”, “Potential Additional Distribution of Zoetis Common Stock”, “Material U.S. Federal Income Tax Consequences” and “Comparison of Stockholder Rights” in the Prospectus, which is incorporated herein by reference.

(b) Purchases. The Exchange Offer is open to all holders of shares of Pfizer common stock who validly tender and do not validly withdraw their shares in a jurisdiction where the Exchange Offer is permitted. Therefore, any officer, director or affiliate of Pfizer who is a holder of shares of Pfizer common stock may participate in the Exchange Offer on the same terms and conditions as all other Pfizer stockholders. Reference is made to the information set forth under the headings “Questions and Answers about the Exchange Offer” and “The Exchange Offer—Terms of the Exchange Offer” in the Prospectus, which is incorporated herein by reference.

 

Item 5.

Past Contacts, Transactions, Negotiations and Agreements.

(e) Agreements Involving the Subject Company’s Securities. Reference is made to the information set forth under the headings “Executive Compensation”, “Securities Ownership”, “2012 Summary Compensation Table” and “2012 Grants of Plan-Based Awards Table” in Pfizer’s Definitive Proxy Statement relating to its Annual Meeting of Shareholders, filed on March 14, 2013, and under

 

2

---

the headings “Agreements Between Pfizer and Zoetis and Other Related Party Transactions” and “Security Ownership of Certain Beneficial Owners and Management of Pfizer and Zoetis—Pfizer Common Stock Ownership by Directors and Executive Officers” in the Prospectus, which is incorporated herein by reference.

 

Item 6.

Purposes of the Transaction and Plans or Proposals.

(a) Purposes. Reference is made to the information under the heading “The Transaction—Reasons for the Exchange Offer” in the Prospectus, which is incorporated herein by reference.

(b) Use of Securities Acquired. The shares of Pfizer common stock acquired by Pfizer in the Exchange Offer will be held as treasury stock, unless and until retired or used for other purposes.

(c) Plans. Reference is made to the information under the heading “Management of Zoetis—Composition of the Board; Classes of Directors” in the Prospectus, which is incorporated herein by reference.

 

Item 7.

Source and Amount of Funds or Other Consideration.

(a) Source of Funds. Reference is made to the information set forth under the headings “Summary—The Exchange Offer”, “The Exchange Offer” and “The Transaction” in the Prospectus, which is incorporated herein by reference.

(b) Conditions. Not applicable.

(d) Borrowed Funds. Not applicable.

 

Item 8.

Interest in Securities of the Subject Company.

(a) Securities Ownership. Reference is made to the information set forth under the heading “Security Ownership of Certain Beneficial Owners and Management of Pfizer and Zoetis” in the Prospectus, which is incorporated herein by reference.

(b) Securities Transactions. Based on the information available to Pfizer as of May 15, 2013, the following table sets forth the transactions in Pfizer common stock by Pfizer and directors and executive officers of Pfizer in the past 60 days:

 

Name		Transaction Date		Number and Type of Securities		Price Per Share				Type of Transaction
Olivier Brandicourt		04-15-2013		33 Phantom Stock Units (Supplemental Savings Plan)		$	30.45			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Olivier Brandicourt		04-30-2013		64 Phantom Stock Units (Supplemental Savings Plan)			29.07			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Olivier Brandicourt		05-15-2013		193 Phantom Stock Units (Supplemental Savings Plan)			29.56			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
M. Anthony Burns		04-25-2013		4,544 Phantom Stock Units			30.26			Annual grant of stock units under the Pfizer award plan for non-employee directors
W. Don Cornwell		04-25-2013		4,544 Phantom Stock Units			30.26			Annual grant of stock units under the Pfizer award plan for non-employee directors
Frank A. D’Amelio		03-28-2013		76 Phantom Stock Units (Supplemental Savings Plan)			28.86			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Frank A. D’Amelio		04-15-2013		74 Phantom Stock Units (Supplemental Savings Plan)			30.45			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Frank A. D’Amelio		04-30-2013		82 Phantom Stock Units (Supplemental Savings Plan)			29.07			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Frank A. D’Amelio		05-15-2013		2,200 Shares of Common Stock			29.23			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		200 Shares of Common Stock			29.24			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		2,400 Shares of Common Stock			29.25			Sale of shares pursuant to a Rule 10b5-1 trading plan

 

3

---

Name		Transaction Date		Number and Type of Securities		Price Per Share				Type of Transaction
Frank A. D’Amelio		05-15-2013		1,700 Shares of Common Stock			29.26			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		2,447 Shares of Common Stock			29.27			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		900 Shares of Common Stock			29.28			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		4,745 Shares of Common Stock			29.29			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		14,497 Shares of Common Stock			29.30			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		5,693 Shares of Common Stock			29.31			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		14,248 Shares of Common Stock			29.32			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		10,913 Shares of Common Stock			29.33			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		8,106 Shares of Common Stock			29.34			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		11,706 Shares of Common Stock			29.35			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		5,103 Shares of Common Stock			29.36			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		2,400 Shares of Common Stock			29.37			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		100 Shares of Common Stock			29.38			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		3,500 Shares of Common Stock			29.39			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		2,700 Shares of Common Stock			29.40			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		6,342 Shares of Common Stock			29.41			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		100 Shares of Common Stock			29.42			Sale of shares pursuant to a Rule 10b5-1 trading plan
Frank A. D’Amelio		05-15-2013		319 Phantom Stock Units (Supplemental Savings Plan)			29.56			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Mikael Dolsten		03-28-2013		73 Phantom Stock Units (Supplemental Savings Plan)			28.86			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Mikael Dolsten		04-15-2013		71 Phantom Stock Units (Supplemental Savings Plan)			30.45			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Mikael Dolsten		04-30-2013		75 Phantom Stock Units (Supplemental Savings Plan)			29.07			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Mikael Dolsten		05-15-2013		107 Phantom Stock Units (Supplemental Savings Plan)			29.56			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Frances D. Fergusson		04-25-2013		4,544 Phantom Stock Units			30.26			Annual grant of stock units under the Pfizer award plan for non-employee directors
Geno J. Germano		03-28-2013		57 Phantom Stock Units (Supplemental Savings Plan)			28.86			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Geno J. Germano		04-15-2013		53 Phantom Stock Units (Supplemental Savings Plan)			30.45			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Geno J. Germano		04-30-2013		61 Phantom Stock Units (Supplemental Savings Plan)			29.07			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Geno J. Germano		05-15-2013		117 Phantom Stock Units (Supplemental Savings Plan)			29.56			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
William H. Gray, III		04-25-2013		4,544 Phantom Stock Units			30.26			Annual grant of stock units under the Pfizer award plan for non-employee directors
Charles H. Hill		03-28-2013		44 Phantom Stock Units (Supplemental Savings Plan)			28.86			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan

 

4

---

Name		Transaction Date		Number and Type of Securities		Price Per Share				Type of Transaction
Charles H. Hill		04-15-2013		44 Phantom Stock Units (Supplemental Savings Plan)			30.45			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Charles H. Hill		04-30-2013		46 Phantom Stock Units (Supplemental Savings Plan)			29.07			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Charles H. Hill		05-15-2013		53 Phantom Stock Units (Supplemental Savings Plan)			29.56			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Helen H. Hobbs		03-28-2013		1,305 Phantom Stock Units			28.86			Acquisition of stock units representing deferred director’s compensation for the first quarter of 2013
Helen H. Hobbs		04-25-2013		4,544 Phantom Stock Units			30.26			Annual grant of stock units under the Pfizer award plan for non-employee directors
Constance J. Horner		04-25-2013		4,544 Phantom Stock Units			30.26			Annual grant of stock units under the Pfizer award plan for non-employee directors
James M. Kilts		03-28-2013		2,099 Phantom Stock Units			28.86			Acquisition of stock units representing deferred director’s compensation for the first quarter of 2013
James M. Kilts		04-25-2013		4,544 Phantom Stock Units			30.26			Annual grant of stock units under the Pfizer award plan for non-employee directors
Douglas M. Lankler		03-28-2013		38 Phantom Stock Units (Supplemental Savings Plan)			28.86			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Douglas M. Lankler		04-15-2013		37 Phantom Stock Units (Supplemental Savings Plan)			30.45			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Douglas M. Lankler		04-30-2013		39 Phantom Stock Units (Supplemental Savings Plan)			29.07			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Douglas M. Lankler		05-15-2013		56 Phantom Stock Units (Supplemental Savings Plan)			29.56			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Freda C. Lewis-Hall		03-28-2013		52 Phantom Stock Units (Supplemental Savings Plan)			28.86			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Freda C. Lewis-Hall		04-15-2013		52 Phantom Stock Units (Supplemental Savings Plan)			30.45			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Freda C. Lewis-Hall		04-30-2013		54 Phantom Stock Units (Supplemental Savings Plan)			29.07			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Freda C. Lewis-Hall		05-15-2013		148 Phantom Stock Units (Supplemental Savings Plan)			29.56			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
George A. Lorch		04-25-2013		4,544 Phantom Stock Units			30.26			Annual grant of stock units under the Pfizer award plan for non-employee directors
Anthony J. Maddaluna		03-28-2013		215 Phantom Stock Units (Supplemental Savings Plan)			28.86			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Anthony J. Maddaluna		04-15-2013		205 Phantom Stock Units (Supplemental Savings Plan)			30.45			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Anthony J. Maddaluna		04-30-2013		228 Phantom Stock Units (Supplemental Savings Plan)			29.07			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Anthony J. Maddaluna		05-15-2013		508 Phantom Stock Units (Supplemental Savings Plan)			29.56			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan

 

5

---

Name		Transaction Date		Number and Type of Securities		Price Per Share				Type of Transaction
Suzanne M. Nora Johnson		04-25-2013		4,544 Phantom Stock Units			30.26			Annual grant of stock units under the Pfizer award plan for non-employee directors
Laurie J. Olson		03-28-2013		34 Phantom Stock Units (Supplemental Savings Plan)			28.86			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Laurie J. Olson		04-15-2013		34 Phantom Stock Units (Supplemental Savings Plan)			30.45			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Laurie J. Olson		04-30-2013		34 Phantom Stock Units (Supplemental Savings Plan)			29.07			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Laurie J. Olson		05-15-2013		36 Phantom Stock Units (Supplemental Savings Plan)			29.56			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Pfizer Inc.		03-16-2013- 05-15-2013*		115,853,033 Common Stock*			29.39	*		Purchase of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		03-28-2013		223 Phantom Stock Units (Supplemental Savings Plan)			28.86			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Ian C. Read		04-15-2013		221 Phantom Stock Units (Supplemental Savings Plan)			30.45			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Ian C. Read		04-30-2013		279 Phantom Stock Units (Supplemental Savings Plan)			29.07			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Ian C. Read		05-15-2013		1,297 Shares of Common Stock			29.29			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		10,503 Shares of Common Stock			29.30			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		705 Shares of Common Stock			29.32			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		1,302 Shares of Common Stock			29.33			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		3,102 Shares of Common Stock			29.34			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		2,900 Shares of Common Stock			29.35			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		8,700 Shares of Common Stock			29.36			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		1,800 Shares of Common Stock			29.37			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		200 Shares of Common Stock			29.38			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		4,800 Shares of Common Stock			29.39			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		2,900 Shares of Common Stock			29.40			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		6,500 Shares of Common Stock			29.41			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		200 Shares of Common Stock			29.42			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		900 Shares of Common Stock			29.46			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		700 Shares of Common Stock			29.47			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		19,400 Shares of Common Stock			29.48			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		200 Shares of Common Stock			29.49			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		3,791 Shares of Common Stock			29.31			Sale of shares pursuant to a Rule 10b5-1 trading plan
Ian C. Read		05-15-2013		1,446 Phantom Stock Units (Supplemental Savings Plan)			29.56			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Stephen W. Sanger		03-28-2013		1,698 Phantom Stock Units			28.86			Acquisition of stock units representing deferred director’s compensation for the first quarter of 2013
Stephen W. Sanger		04-25-2013		4,544 Phantom Stock Units			30.26			Annual grant of stock units under the Pfizer award plan for non-employee directors

 

*	From March 16 - May 15, 2013, Pfizer repurchased an aggregate of 115,853,033 shares of Pfizer common stock at a weighted average price of $29.3886 per share pursuant to a Rule 10b5-1 trading plan.

 

6

---

Name		Transaction Date		Number and Type of Securities		Price Per Share				Type of Transaction
Amy W. Schulman		03-28-2013		60 Phantom Stock Units (Supplemental Savings Plan)			28.86			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Amy W. Schulman		04-15-2013		59 Phantom Stock Units (Supplemental Savings Plan)			30.45			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Amy W. Schulman		04-30-2013		62 Phantom Stock Units (Supplemental Savings Plan)			29.07			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Amy W. Schulman		05-15-2013		4,500 Shares of Common Stock			29.29			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		3,800 Shares of Common Stock			29.30			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		2,400 Shares of Common Stock			29.31			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		5,700 Shares of Common Stock			29.32			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		2,259 Shares of Common Stock			29.33			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		5,268 Shares of Common Stock			29.34			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		10,598 Shares of Common Stock			29.35			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		3,999 Shares of Common Stock			29.36			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		3,807 Shares of Common Stock			29.37			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		1,956 Shares of Common Stock			29.38			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		3,802 Shares of Common Stock			29.39			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		4,701 Shares of Common Stock			29.40			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		10,408 Shares of Common Stock			29.42			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		3,592 Shares of Common Stock			29.42			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		2,005 Shares of Common Stock			29.43			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		805 Shares of Common Stock			29.44			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		100 Shares of Common Stock			29.45			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		300 Shares of Common Stock			29.46			Sale of shares pursuant to a Rule 10b5-1 trading plan
Amy W. Schulman		05-15-2013		94 Phantom Stock Units (Supplemental Savings Plan)			29.56			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Sally Susman		03-28-2013		55 Phantom Stock Units Supplemental Savings Plan)			28.86			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Sally Susman		04-15-2013		54 Phantom Stock Units (Supplemental Savings Plan)			30.45			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Sally Susman		04-30-2013		56 Phantom Stock Units (Supplemental Savings Plan)			29.07			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Sally Susman		05-15-2013		66 Phantom Stock Units (Supplemental Savings Plan)			29.56			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
Marc Tessier-Lavigne		04-25-2013		4,544 Phantom Stock Units			30.26			Annual grant of stock units under the Pfizer award plan for non-employee directors
John D. Young		03-28-2013		50 Phantom Stock Units (Supplemental Savings Plan)			28.86			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
John D. Young		04-15-2013		51 Phantom Stock Units (Supplemental Savings Plan)			30.45			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
John D. Young		04-30-2013		53 Phantom Stock Units (Supplemental Savings Plan)			29.07			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan
John D. Young		05-15-2013		62 Phantom Stock Units (Supplemental Savings Plan)			29.56			Periodic Acquisition of stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan

 

7

---

Item 9.

Persons/Assets, Retained, Employed, Compensated or Used.

(a) Solicitations or recommendations. Reference is made to the information set forth under the heading “The Exchange Offer—Fees and Expenses” in the Prospectus, which is incorporated herein by reference.

 

Item 10.

Financial Statements.

(a) Financial Information. Reference is made to the information set forth under the headings “Summary—Selected Historical Financial Data For Pfizer and Zoetis” and “Incorporation by Reference” in the Prospectus, which is incorporated herein by reference. The financial information included as Item 8 and Exhibit 12 in Pfizer’s Annual Report on Form 10-K for the annual period ending December 31, 2012, as amended, as well as the financial statements and other financial information included as Part I—Item 1 and Exhibit 12 in Pfizer’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013, are incorporated herein by reference.

(b) Pro Forma Information. Pro forma financial information for Pfizer has not been provided because Pfizer has determined that such information would not be material. Based on Pfizer’s historical ownership of Zoetis, the data incorporated by reference in Item 10(a) is impacted by assets, liabilities, results of operations or cash flows attributable to Zoetis. Upon completion of the exchange offer, assuming it is fully subscribed, Zoetis’s historical results will be shown, in Pfizer’s financial statements, as discontinued operations and, in subsequent periods, Pfizer’s financial statements will no longer reflect the assets, liabilities, results of operations and cash flows attributable to Zoetis. However, pro forma financial information for Zoetis giving effect to certain transactions, including, among other transactions, the Exchange Offer, have been included in the Prospectus. Reference is made to the information set forth under the heading “Zoetis Inc. Unaudited Pro Forma Condensed Financial Statements” in the Prospectus, which is incorporated herein by reference.

 

Item 11.

Additional Information.

(a) Agreements, Regulatory Requirements and Legal Proceedings.

(1) None.

(2) Reference is made to the information set forth under the headings “Summary”, “The Transaction” and “Business of Zoetis” in the Prospectus, which is incorporated herein by reference.

(3) Reference is made to the information set forth under the headings “Summary” and “The Transaction” in the Prospectus, which is incorporated herein by reference.

(4) Not applicable.

(5) None.

(b) Other Material Information. Reference is made to the information set forth in the Prospectus, which is incorporated herein by reference.

 

Item 12.

Exhibits.

 

Exhibit Number		Description
(a)(1)(i)		Form of Letter of Transmittal (incorporated by reference to Exhibit 99.1 to Zoetis Inc.’s Registration Statement on Form S-4 (Registration No. 333-188750), filed with the Securities and Exchange Commission (the “Commission”) on May 22, 2013 (the “Registration Statement”).
(a)(1)(ii)		Instructions for Letter of Transmittal (incorporated by reference to Exhibit 99. 2 to Zoetis Inc.’s Amendment No. 1 to the Registration Statement filed with the Commission on June 3, 2013 (“Amendment No. 1”)).
(a)(1)(iii)		Form of Notice of Guaranteed Delivery (incorporated by reference to Exhibit 99.3 to the Registration Statement).
(a)(1)(iv)		Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies, Custodians and Similar Institutions (incorporated by reference to Exhibit 99.4 to the Registration Statement).
(a)(1)(v)		Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies, Custodians and Similar Institutions (incorporated by reference to reference to Exhibit 99.5 to the Registration Statement).

 

8

---

(a)(1)(vi)		Form of Notice of Withdrawal (incorporated by reference to Exhibit 99.6 to Amendment No. 1).
(a)(4)(i)		Press Release by Pfizer Inc., dated May 22, 2013 (incorporated by reference to Pfizer Inc.’s Form 425 filing with the SEC on May 22, 2013).
(a)(4)(ii)		Prospectus, dated June 3, 2013 (incorporated by reference to Amendment No. 1).
(a)(5)(i)		Form of Notice to Participants in Pfizer Savings Plans (incorporated by reference to Exhibit 99.7 to the Registration Statement).
(h)(i)		Opinion of Skadden, Arps, Slate, Meagher & Flom LLP regarding certain tax consequences of the exchange offer (incorporated by reference to Exhibit 8.1 to the Registration Statement).

 

Item 13.

Information required by Schedule 13E-3.

Not Applicable.

 

9

---

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: June 3, 2013

 

 

10

---

EXHIBIT INDEX

 

Exhibit Number		Description
(a)(1)(i)		Form of Letter of Transmittal (incorporated by reference to Exhibit 99.1 to Zoetis Inc.’s Registration Statement on Form S-4 (Registration No. 333-188750), filed with the Securities and Exchange Commission (the “Commission”) on May 22, 2013 (the “Registration Statement”).
(a)(1)(ii)		Instructions for Letter of Transmittal (incorporated by reference to Exhibit 99. 2 to Zoetis Inc.’s Amendment No. 1 to the Registration Statement filed with the Commission on June 3, 2013 (“Amendment No. 1”)).
(a)(1)(iii)		Form of Notice of Guaranteed Delivery (incorporated by reference to Exhibit 99.3 to the Registration Statement).
(a)(1)(iv)		Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies, Custodians and Similar Institutions (incorporated by reference to Exhibit 99.4 to the Registration Statement).
(a)(1)(v)		Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies, Custodians and Similar Institutions (incorporated by reference to reference to Exhibit 99.5 to the Registration Statement).
(a)(1)(vi)		Form of Notice of Withdrawal (incorporated by reference to Exhibit 99.6 to Amendment No. 1).
(a)(4)(i)		Press Release by Pfizer Inc., dated May 22, 2013 (incorporated by reference to Pfizer Inc.’s Form 425 filing with the SEC on May 22, 2013).
(a)(4)(ii)		Prospectus, dated June 3, 2013 (incorporated by reference to Amendment No. 1).
(a)(5)(i)		Form of Notice to Participants in Pfizer Savings Plans (incorporated by reference to Exhibit 99.7 to the Registration Statement).
(h)(i)		Opinion of Skadden, Arps, Slate, Meagher & Flom LLP regarding certain tax consequences of the exchange offer (incorporated by reference to Exhibit 8.1 to the Registration Statement).

 

11